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ABSTRACT
Objective To quantify the change in prescribing of
antibiotic prophylaxis before invasive dental procedures
for patients at risk of infective endocarditis, and any
concurrent change in the incidence of infective
endocarditis, following introduction of a clinical guideline
from the National Institute for Health and Clinical
Excellence (NICE) in March 2008 recommending the
cessation of antibiotic prophylaxis in the United Kingdom.
Design Before and after study.
Setting England.
Population All patients admitted to hospital in England
with a primary or secondary discharge diagnosis of acute
or subacute infective endocarditis.
Main outcome measuresMonthly number of
prescriptions for antibiotic prophylaxis consisting of a
single 3 g oral dose of amoxicillin or a single 600 mg oral
dose of clindamycin, and monthly number of cases of
infective endocarditis, infective endocarditis related
deaths in hospital, or cases of infective endocarditis with
a possible oral origin for streptococci.
Results After the introduction of the NICE guideline there
was a highly significant 78.6% reduction (P<0.001) in
prescribing of antibiotic prophylaxis, from a mean 10277
(SD 1068) prescriptions per month to 2292 (SD 176).
Evidence that the general upward trend in cases of
infective endocarditis before the guideline was
significantly altered after the guideline was lacking
(P=0.61). Using a non-inferiority test, an increase in the
number of cases of 9.3% or more could be excluded after
the introduction of the guideline. Similarly an increase in
infective endocarditis related deaths in hospital of 12.3%
or more could also be excluded.
Conclusion Despite a 78.6% reduction in prescribing of
antibiotic prophylaxis after the introduction of the NICE
guideline, this study excluded any large increase in the
incidence of cases of or deaths from infective
endocarditis in the two years after the guideline. Although
this lends support to the guideline, ongoing data
monitoring is needed to confirm this, and further clinical
trials should determine if antibiotic prophylaxis still has a
role in protecting some patients at particularly high risk.
INTRODUCTION
Infective endocarditis is a rare disease with a highmor-
bidity andmortality.1 Formore than50 years antibiotic
prophylaxis before invasive procedures has been the
primary focus for preventing infective endocarditis
and remains the standard of care for patients with the
disease in most parts of the world.2 3 The rationale for
such treatment is to reduce or eliminate the bacterae-
mia that may result from such procedures.4 A particu-
lar focus is on antibiotic prophylaxis before dental
procedures, as oral streptococci have been implicated
in between 18% and 65% of cases of infective endo-
carditis, although most studies suggest the proportion
is closer to 35-45%.5-9 Regardless, little or no firm scien-
tific evidence supports the effectiveness of antibiotic
prophylaxis in preventing infective endocarditis,4 and
two case-control studies provide evidence that dental
treatment is unlikely to be a risk factor.8 9 Some authors
therefore suggest that the current focus on antibiotic
prophylaxis is an unproved, expensive, andpotentially
harmful standard of care, whereas others argue that it
prevents cases of infective endocarditis.2 10-13 Owing to
ethical andmedicolegal issues, cost, and the large num-
ber of patients necessary to achieve statistically signifi-
cant results, a randomised placebo controlled trial of
antibiotic prophylaxis has never been attempted.14
InMarch 2008, theNational Institute forHealth and
Clinical Excellence (NICE) in the United Kingdom
produced controversial new guidance recommending
the cessation of antibiotic prophylaxis for all patients at
risk of infective endocarditis undergoing dental and a
wide range of other invasive procedures.15-17 Although
the American Heart Association2 and the European
Society for Cardiology3 changed their guidelines
around the same time, they did not recommend the
complete cessationof antibiotic prophylaxis. Both con-
tinued to recommend antibiotic prophylaxis for
patients with prosthetic heart valves undergoing inva-
sive dental procedures, patients with cardiac valves
repaired using prosthetic material, and patients with
significant congenital heart lesions, a heart transplant
with valvular lesions, or a history of endocarditis.
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We hypothesised that by studying national prescrib-
ing data as well as data recorded for all inpatient hospi-
tal activity in theUnitedKingdom,wewould be able to
quantify the effect of the new NICE guideline on pre-
scribing of antibiotic prophylaxis and the incidence of
infective endocarditis. We describe the effect of the
guideline on the prescribing of antibiotic prophylaxis
in England and the changes in the incidence of cases of
infective endocarditis and deaths from the disease in
hospital over that period.
METHODS
Prior to the introduction of the NICE guideline in
March 2008 a single 3 g oral dose of amoxicillin or a
600mg oral dose of clindamycin was used as antibiotic
prophylaxis to prevent infective endocarditis in people
at risk undergoing invasive dental procedures. We
obtained national monthly prescribing data for all
such prescriptions issued in England between January
2004 and April 2010 (25 months after the introduction
of the guideline), from the prescription pricing division
of the NHS Business Services Authority (www.ppa.
org.uk/ppa/ppa_main.htm).
Figures on the incidence of infective endocarditis in
Englandwere obtained fromnational data on inpatient
hospital activity from January 2000 until April 2010.
All patients admitted to hospitals in the United King-
dom have standard data recorded, including their pri-
mary discharge diagnosis and up to 12 secondary
diagnoses, using the ICD-10 coding system (http://
apps.who.int/classifications/apps/icd/icd10online).
These anonymised data are reported to the data ware-
house of the SecondaryUses Service (www.connecting
forhealth.nhs.uk/systemsandservices/sus). We used
Dr Foster Intelligence (www.drfosterintelligence.co.
uk), a public-private partnership health service infor-
mation and intelligence organisation, to access and
assess the data from the Secondary Uses Service. The
data presented are for England only.
We identified all patients, including those who died
in hospital, with a primary or secondary discharge
diagnosis of “acute or subacute infectious endo-
carditis” (ICD-10 I33.0). We also identified patients
with such a diagnosis where a streptococcal or staphy-
lococcal cause was also recorded (ICD-10 A40, A41
codes for septicaemia or B95 supplementary causal
organism codes). Codes A40.0 to A40.3 and B95.0 to
B95.3, respectively, identify group A, B, and D strep-
tococci and Streptococcus pneumoniae as causal organ-
isms. Codes A40.4, A40.5, B95.4, and B95.5 identify
other streptococci or unspecified streptococci as the
cause of disease. For analysis purposes we grouped
cases of infective endocarditis with an A40.4, A40.5,
B95.4, or B95.5 code as cases with a possible oral strep-
tococcal cause. For comparisonwe also identified cases
with a staphylococcal cause by grouping cases with
codes A41.0 to A41.2 or B95.6 to B95.8.
By searching individual patient level data we were
able to identify when patients admitted to one hospital
were transferred to another as part of their
management. We counted such continuous periods
of illness, known as “superspells,” only once.
Statistical analysis
We plotted graphically data on monthly prescribing
and incidence of infective endocarditis. In each case
we also plotted the moving average figure for every
three months and, for the incidence data on infective
endocarditis, the linear trend lines and lines represent-
ing 2 standard deviations either side of the trend line
for the periods before and after the introduction of the
guideline.
The biostatistician (DJC) analysed data up to March
2008 and prepared the plan for testing the subsequent
data before being given access to such data.
We used a Poisson regression model to investigate
the monthly trends in cases of infective endocarditis
and deaths in hospital. This assumed a proportional
change and allowed control for population size. Popu-
lation data for England were obtained fromwww.statis
tics.gov.uk/hub/population/index.html and we fitted
a cubic spline function to obtain monthly estimates of
population size. We investigated non-linear trends by
adding a quadratic term in the Poisson regression
model, but as this term was not statistically significant
for any of the outcomes it was dropped from the mod-
els. To test for over-dispersion we carried out likeli-
hood ratio tests between “standard” Poisson
regressions and negative binomial regressions, with
all other settings equal. The log likelihood ratios
reported for the negative binomial regressions were
lower than those reported for the standard Poisson
regressions, which indicated (without the need for a
likelihood ratio test) that negative binomial regressions
did not offer an improvement over Poisson regres-
sions.
For the primary analysis of cases of infective endo-
carditis and deaths we used a “non-inferiority” test.
This requires specification of a margin of indifference.
We determined this by examining the number of cases
and variability in the data before March 2008—that is,
the limitations of the data. It was not determined by
deciding what might be a clinically meaningful margin
of indifference.
An upper limit for the acceptable increase in the
number of cases was therefore specified based on the
quality of the data. For the non-inferiority test we
regarded the counts of cases and deaths as continuous
variables. Because of the upward trend in the outcomes
before the guideline change, we based the limits on the
number of cases or deaths in March 2008 estimated
from our fitted Poisson regression model. We used
the monthly data before the guideline change to set
the margin for the mean of the 25 months of data
since the change.
Based on the variability of the monthly data before
the changewe set as themargin a 15% increase over the
fitted number for cases and deaths. To carry out the test
we constructed a 95% confidence interval for the
monthly mean number of cases or deaths for the
25 months after the guideline change. If the upper
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limit of the confidence interval corresponded to an
increase of less than 15% over the model’s estimate
for the number of cases or deaths for March 2008
(that is, <139.8 or <22.4, respectively) we considered
that the number of cases or deaths had not increased
significantly.
Prespecified secondary tests of whether cases of
infective endocarditis or deaths had increased since
the introduction of the guideline were: testing whether
there was an increase in the time trend in the Poisson
regression models, and noting whether in 17 or more
months from April 2008 to April 2010 the number of
cases or deaths exceeded the fitted value for March
2008 (121.6 cases or 19.5 deaths). The probability of
25 independent counts of 17 exceeding this level was
0.22 (that is, <5%) and so we set 17 as the test statistic.
RESULTS
From mid-2000 to mid-2009, the population of Eng-
land increased at an annual rate of 0.57%, from
49 233 300 to 51 809 700 (Office for National Statis-
tics).
Changes in prescribing of antibiotic prophylaxis
In the 12 months after the introduction of NICE clin-
ical guideline No 64, the prescribing of antibiotic pro-
phylaxis for infective endocarditis declined rapidly
(fig 1). To compare more stable periods of prescribing
for antibiotic prophylaxis, the 12 months before the
introduction of the guideline was compared with the
most recent 12 months of prescribing data for 14 to
25months inclusive after the introduction of the guide-
line. This comparison provided a 78.6% reduction in
prescribing, from a mean 10 727 (SD 1068) before the
introduction of the guideline to 2292 (SD 176) after. In
the 12months before the guideline, prescribing of anti-
biotic prophylaxis by dentists accounted for 91.9% of
prescriptions for antibiotic prophylaxis, with other
prescribers accounting for the remaining 8.1% (general
medical practitioners 7.8%, hospitals 0.2%, and nurses
0.1%). However, 14-25 months after the introduction
of the guideline, the number of prescriptions issued by
dentists decreased significantly, from a mean 9859 per
month to 1977 (a decrease of 79.9%, P<0.001). Over
the same period the number of prescriptions issued by
other prescribers significantly decreased, from a mean
868 per month to 315 (a decrease of 63.7%, P<0.001).
Number of cases and in-hospital deaths
Before guideline change
The table gives estimated annual percentage changes
in the number of cases and number of deaths. From
January 2000 to March 2008, there was an increasing
trend in the number of cases of infective endocarditis
(P<0.001), cases possibly attributable to oral strepto-
cocci (P<0.001), and deaths from infective endo-
carditis (P=0.008). The number of cases was
significantly correlated with the number of deaths
(Spearman correlation coefficient 0.46, P=0.001).
After guideline change
Evidence was lacking that the upward trend in cases of
infective endocarditis had changed (P=0.61 for the dif-
ference between the trend before and after the guide-
line change, table and fig 2) since the introduction of
the guidelines and the precipitous decrease in prescrib-
ing of antibiotic prophylaxis.
The average monthly number of cases of infective
endocarditis for the 25 months from April 2008 was
125.5 (SD 17.59). The upper limit for the 95% confi-
dence interval for the mean was 132.9. As this is less
than the prespecified limit of 139.8, the possibility of a
15% increase in cases can be excluded.More precisely,
the possibility of a 9.3% increase can be excluded. The
number of cases of infective endocarditis was greater
than the fitted number for March 2008 in just 13 of the
25 subsequent months and did not exceed the preset
value of 17.
Evidence is lacking that the upward trend in deaths
changed after the introduction of the guideline
(P=0.45, table). The average number of deaths from
infective endocarditis per month for the 25 months
from April 2008 was 20.0 (SD 4.62). The upper limit
for the 95% confidence interval for the mean was 21.9.
As this is less than the prespecified limit of 22.4, the
possibility of a 15% increase in deaths from infective
endocarditis can be excluded.More precisely, the pos-
sibility of a 12.3% increase in deaths can be excluded.
The number of deaths was greater than the fitted num-
ber for March 2008 in just 13 of the 25 subsequent
months and did not exceed the preset value of 17.
Therewas also no evidence of a significant change in
the upward trend in the number of cases possibly attri-
butable to oral streptococci (P=0.66), whereas the rate
Estimated annual percentage change in cases of infective endocarditis before and after the introduction of the National Institute for Health and Clinical
Excellence guideline recommending cessation of antibiotic prophylaxis
Variables Before guideline change (95%CI) P value* After guideline change (95% CI) P value† Difference (95% CI)‡
All infective endocarditis cases 3.82 (3.04 to 4.61) <0.001 2.72 (−0.94 to 6.52) 0.61 −1.1 (−3.98 to 1.91)
Oral streptococcal cases 8.41 (6.66 to 10.19) <0.001 10.38 (2.93 to 18.36) 0.66 1.97 (−3.73 to 8.17)
Staphylococcal cases 9.24 (7.45 to 11.06) <0.001 1.49 (−5.66 to 9.19) 0.08 −7.75 (−13.11 to −1.87)
Deaths from infective endocarditis 2.55 (0.65 to 4.48) 0.008 6.64 (−2.50 to 16.64) 0.45 4.09 (−3.15 to 12.16)
All estimates in a row are from a single Poisson regression model, adjusting for population size, and with one term for months since January 2000 and another for months since guideline
change.
*P value for test of term for change before introduction of guideline.
†P value for test of whether term after guideline change is 0—that is, whether annual percentage change differs between before and after the guideline was introduced.
‡Percentage difference in annual percentage increase in cases before and after guideline was introduced.
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of increase in cases due to staphylococci slowed non-
significantly (P=0.08; table and fig 3).
DISCUSSION
Antibiotic prophylaxis prescribing for infective endo-
carditis in the United Kingdom stayed relatively con-
stant until the introduction of the NICE guideline in
March 2008; most (91.9%) prescribing was by dental
practitioners. After the introduction of the guideline a
large (78.6%) and rapid decrease occurred in prescrib-
ing of antibiotic prophylaxis. However, we did not
detect a significant increase in the number of infective
endocarditis cases above the long term baseline trend
over this period. Neither was there a significant
increase in the rate of infective endocarditis related
deaths in hospital nor a significant increase in the num-
ber of cases due to streptococci of possible oral origin.
Limitations of the study
The study has several limitations. Firstly, it was retro-
spective and limited to England and therefore may not
be generalisable to other populations. Secondly, the
data rely on hospital coding. In the United Kingdom,
data are collected on every patient admitted to hospi-
tal, and the coding is done by trained and accredited
staff. Although these data can be subject to coding
errors, the coding has been shown to be more reliable
and complete in capturing data on, for example, all
cases of vascular surgery than a national research data-
base specifically designed for that purpose.18 Further-
more, as the coding was done independently of the
study it was not subject to study bias or influenced in
anyway by the introduction of theNICE guideline. As
the study samplewas based on national data, the size of
the dataset and the consistency of the process are likely
to average out any error.
Although patients with infective endocarditis may
present to different hospital specialties and the disease
maybe difficult to diagnose initially, data fromhospital
episode statistics records only the discharge diagnosis
and should therefore reflect as accurately as possible
the actual number of cases treated. None the less,
because the diagnosis of endocarditis is sometimes
uncertain, some cases will undoubtedly have been
missed and others will have been erroneously labelled
as endocarditis. The number of deaths from infective
endocarditis in hospital were obtained from hospital
episode statistics data, defining the status at discharge
from hospital (dead or alive). Thus the data reflect
deaths that are the immediate result of a hospital
admission for infective endocarditis and will not have
captured deaths before admission or deaths at home as
a result of the late complications of the disease. The
mortality data are therefore not directly comparable
to long term follow-up studies of patients with infective
endocarditis.
Thirdly, there is no requirement to record anything
other than a primary diagnosis for each patient; a cau-
sal organismwas recorded in only around 70%of cases
towards the end of the study. In addition there is no
specific ICD-10 code for viridians group streptococci.
We therefore had to use codes for “unspecified” or
“other” streptococci to identify cases of infective
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Fig 1 | Total number of prescriptions for antibiotic prophylaxis (amoxicillin 3 g or clindamycin
600 mg) dispensed each month by type of prescriber. Red lines represent moving average
figure for prescriptions every three months
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Fig 2 | Monthly number of cases of infective endocarditis. Also plotted are separate lines for linear trend within 2 standard
deviations (broken lines) for periods before and after introduction of NICE guideline. Red lines represent moving average figure
for number of cases every three months
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endocarditis with a possible viridians group strepto-
coccal cause. Nevertheless, these codes exclude
group A, B, and D streptococci and S pneumoniae and,
given the microbiology of the oral cavity and infective
endocarditis, it is possible that oral viridians group
streptococci account for a high proportion of the
organisms in this group.19 20
Fourthly, although 35-45% of cases of infective
endocarditis are caused by oral viridians group
streptococci,5-9 gooddata are lacking on the proportion
resulting froman invasive dental procedure.However,
the strategy of giving antibiotic prophylaxis to prevent
infective endocarditis is based on the premise that a
high proportion of these cases result from oral bacteria
entering the circulation during dental procedures. An
alternative view, however, is growing that oral bacteria
continuously enter the circulation21 22 as a result of
daily activities such as chewing food and tooth brush-
ing, and thesemay be farmore important causes of oral
viridians group streptococci associated cases of infec-
tive endocarditis. If true, theproportionof cases caused
by invasive dental procedures could be low. The rea-
lity could, however, lie anywhere between these two
extremes.
Without accurate data on the proportion of cases
caused by dental procedures it is difficult for statistical
analysis purposes to predefine a clinically relevant
level of change after the cessation of antibiotic prophy-
laxis, or to determine the sample size needed to detect
the change.Using the premise that a highproportion of
cases are caused by dental procedures, a large increase
in the number of cases would be expected if antibiotic
prophylaxis was stopped and was effective, and a com-
paratively small population would be needed to detect
a statistically significant change. On the other hand, if
the number of cases caused by dental procedures was
small, it would require an infinitely large population to
detect any increase in the number. Indeed, to exclude a
1% increase in the incidence of infective endocarditis
above the baseline trend, assuming a similar incidence
of infective endocarditis and variability in the numbers
of cases on a month by month basis, would require a
study population of 478.5 million people. For this rea-
son, evenwith a study covering the entire populationof
England, the possibility of a small increase in cases
after cessation of antibiotic prophylaxis cannot be
excluded. However, that we identified no significant
increase in cases in a population of this size, despite a
large decrease in prescribing of antibiotic prophylaxis,
suggests that invasive dental procedures are unlikely to
account for a high proportion of the cases.
Because of this, and because of the nature of the sta-
tistical test we applied, we used the quality of the avail-
able data to determine the limits of detection rather
than estimate a clinically relevant level of change.
The 15% margin of error set for the statistical analysis
was determined a priori based on the variability in
monthly incidence figures for cases of and deaths
from infective endocarditis in the period before
March 2008. After the analysis was done, however,
we were able to exclude a 9.3% increase in the number
of cases and a 12.3% increase in deaths in the setting of
a 78.6% decrease in prescribing of antibiotic prophy-
laxis. Although oral viridians group streptococci are
likely to account for only 35-45% of cases, if antibiotic
prophylaxis was effectivewewould expect the number
of cases and deaths to increase significantly more than
9.3% and 12.3%, respectively, and the number of cases
with a probable oral streptococcal origin to rise much
higher.
There is the concern that the period of follow-upwas
not long enough. However, in over 90% of cases the
incubation period for infective endocarditis is less than
six weeks, and other studies have used threemonths as
the cut off for capturing all cases of infective endo-
carditis that will develop after exposure to the risk of
infection.8 9 We therefore believe that if antibiotic pro-
phylaxis was effective in preventing infective endo-
carditis the large decrease in prescribing of antibiotic
prophylaxis that occurred after the introduction of the
NICE guideline would have resulted in a detectable
increase in cases during the 25 months of the study.
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Fig 3 | Proportion of infective endocarditis cases recorded each month with a code for streptococci or staphylococci as cause.
Red lines represent moving average figure for cases every three months
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Any such change should have been particularly notice-
able among those cases where the causal organismwas
of possible oral streptococcal origin. Regardless, we
intend to periodically monitor the rate of endocarditis
in the English population over time.
The 78.6% decrease in prescribing of antibiotic pro-
phylaxis in the months after the introduction of the
guideline was large and suggests much better compli-
ance than is often seen after policy changes in medi-
cine. Compliance was particularly good among
dentists who, as well as being strongly urged to adopt
the new guidelines by the chief dental officer, NICE,
and the dental press, were advised by the malpractice
insurance organisations that it would be difficult to
defend cases where the new guidelines had not been
followed. A residual level of prescribing does, how-
ever, seem to persist at around 20% of the level before
the guideline. There are several possible explanations
for this. Firstly, the guideline allows antibiotic prophy-
laxis to be prescribed to patients who have previously
received it and insist on continuing to have it, even
after the rationale for the change in policy has been
fully explained. Secondly, anecdotal evidence suggests
that some cardiologists are pressurising dentists or,
where dentists refuse to prescribe, the patient’s general
medical practitioner to provide antibiotic prophylaxis
for patients they regard at particularly high risk of
infective endocarditis, such as patients with significant
congenital heart lesions, prosthetic heart valves, or a
history of infective endocarditis. In other words,
some clinicians in the United Kingdommay be imple-
menting the European Society for Cardiology or
American Heart Association guidelines rather than
the NICE guideline.23 Finally, anecdotal evidence
also suggests that a small proportion of dentists in the
UnitedKingdomprescribe a 3 g dose of amoxicillin (or
600mgdose of clindamycin) to treat acute dental infec-
tions. The precise contribution of each of these expla-
nations to the residual 20%prescribing figure is hard to
quantify.
Over the past 10 years a general move has been to
reduce antibiotic prescribing to save cost and to pre-
vent the development of antibiotic resistant bacteria.
Although this could have played a part in the reduction
in prescribing of antibiotic prophylaxis, it seems unli-
kely given the size and suddenness of the reduction, its
coincidence with the introduction of the NICE guide-
line, the low cost of a single dose of amoxicillin or clin-
damycin, and national prescribing data that show a
slight increase in the general prescribing of penicillins
and macrolide antibiotics over the same period.
The results of this analysis cover a large group of
patients for whom antibiotic prophylaxis was pre-
scribed before the introduction of the NICE guideline.
Our results suggest that for most of these patients,
including those with a history of rheumatic fever or a
heart murmur, there may be little or no benefit in giv-
ing antibiotic prophylaxis to prevent infective endo-
carditis. However, because we cannot exclude the
possibility that residual antibiotic prophylaxis pre-
scribing targets those perceived to be at highest risk
of infective endocarditis, it does not completely tackle
the problem of whether a subset of patients, particu-
larly those with prosthetic heart valves or a history of
infective endocarditis, might still benefit from anti-
biotic prophylaxis. To more directly answer this ques-
tion a carefully designed, randomised, placebo
controlled trial of antibiotic prophylaxis in these
patients would be required.
Interpretation of the findings
Given that oral viridians group streptococci are clearly
implicated in some cases of infective endocarditis, our
findings provide support for the growing view that the
frequent episodes of bacteraemia that follow daily rou-
tines such as eating and tooth brushing may be a
greater risk factor for the development of infective
endocarditis than the transient bacteraemia that fol-
lows an invasive dental procedure.21 Furthermore,
the evidence that the bacteraemia after tooth brushing
is significantly greater and more common in patients
with poor oral hygiene and gingival disease22 suggests
that improving oral hygienemight bemore effective at
reducing the number of cases caused by oral bacteria
than providing antibiotic prophylaxis for invasive den-
tal procedures.9
Conclusion
Our data suggest that despite a substantial decrease in
prescribing of antibiotic prophylaxis in England since
the introduction of NICE guideline No 64 in March
2008 there has been no significant increase in the num-
ber of cases of infective endocarditis, as measured
using data from hospital episode statistics.
Some clinicians remain concerned that the NICE
recommendation to stop antibiotic prophylaxis in the
United Kingdom, and the reduced number of patients
receiving antibiotic prophylaxis in the United States
and Europe as a result of the restriction of antibiotic
prophylaxis to patients thought to be at high risk in
the latest American Heart Association2 and European
Society of Cardiology3 guidelines, will result in an
increased incidence of infective endocarditis.
Although one small study found no cause for concern
after the change in the American Heart Association
guidelines24 the present trial is the first large scale
study to evaluate the effect of the NICE guideline
recommendation to stop antibiotic prophylaxis to pre-
vent infective endocarditis.
Although these findings lend support to the NICE
guideline recommendations and suggest that antibiotic
prophylaxis before invasive dental procedures is unli-
kely to be of value in preventing infective endocarditis
in patients with a history of rheumatic fever or a heart
murmur, our findings do not exclude the possibility
that a small number of patients at highest risk, such as
those with prosthetic valves, might benefit. Ongoing
monitoring of the data is required for confirmation,
and further studies are needed to determine if anti-
biotic prophylaxis has a role in protecting a small
group of patients at highest risk from infective endo-
carditis.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Previous policy in the United Kingdomwas to provide antibiotic prophylaxis to patients at risk
of infective endocarditis before invasive dental procedures
Antibiotic prophylaxis for patients thought to be at high risk of infective endocarditis is still
the policy in most other parts of the world
In March 2008 NICE recommended the complete cessation of antibiotic prophylaxis before
dental and other invasive procedures
WHAT THIS STUDY ADDS
After the introduction of NICE clinical guideline No 64 a large (78.6%) and rapid decrease
occurred in prescribing of antibiotic prophylaxis
Despite this reduction, no large increase occurred in the incidence of infective endocarditis
cases or deaths in the two years after the guideline was introduced
The findings support the cessation of prescribing of antibiotic prophylaxis recommended by
the guideline
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